MedTrace Logo

Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis

NCT04008069 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-10-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the effectiveness and the safety of sarilumab in patients with glucocorticoid-dependent sarcoidosis.

Conditions

  • Sarcoidosis

Interventions

DRUG

Sarilumab

Sarilumab 200 mg administered subcutaneously

DRUG

Placebo

Placebo administered subcutaneously

Sponsors & Collaborators

Principal Investigators

  • Matthew Baker, MD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-03
Primary Completion
2022-07-26
Completion
2022-09-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04008069 on ClinicalTrials.gov